New platform maps Sweden’s place in the global ATMP landscape
November 9, 2026
The ATMP map is a new public platform that shows where Sweden stands in research on advanced therapies, and how that research moves into clinical trials, patents and policy.
A new platform, atmpmap.com, gives an overview of ATMP research worldwide and shows where Sweden stands in the field.
The ATMP map is built on more than 900,000 scientific publications from 192 countries, covering 1990–2024. It traces how research is used further: in clinical trials, patents, policy documents and public debate.
What the map shows about Sweden:
- Volume: Sweden has published about 15,000 ATMP papers, ranking 15th in the world.
- Impact: Sweden ranks 7th in the world for highly cited ATMP papers.
- Gene editing: Over the past two decades, Sweden has ranked 1st in the world in DNA tailoring, such as CRISPR gene editing.
- Research hubs: Stockholm–Uppsala, Lund–Malmö and Gothenburg are involved in about nine in ten Swedish ATMP papers.
- Clinical use: Swedish ATMP research is extensively cited in clinical trials worldwide, highlighting its contribution to the global development of advanced therapies. Yet much of the clinical activity linked to this research takes place outside Sweden, particularly in the United States.
At SCALE, we work to build ATMP skills and collaboration in West Sweden. The map gives a clear picture of where Swedish research is strong, and where more is needed to turn that research into treatments for patients.
The platform was built by Yotam Sofer, House of Innovation, Stockholm School of Economics, together with a consortium of Lund University, Karolinska Institutet, KTH Royal Institute of Technology, Stockholm School of Economics, Uppsala University, University of Gothenburg, Karolinska University Hospital, Skåne University Hospital and ATMP Sweden, with industrial partners CCRM Nordic, BioLamina and other innovation actors and companies.
Explore the map: https://www.atmpmap.com/
For more information
The platform: Yotam Sofer, House of Innovation, Stockholm School of Economics, yotam.sofer@hhs.se
The consortium: Karl-Johan Malmberg, Karolinska Institutet, kalle.malmberg@ki.se, or Anna Falk, Lund University, anna.falk@med.lu.se